Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees.  The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.

Bristol Myers Squibb Co. terlibat dalam penemuan, pengembangan, lisensi, manufaktur, pemasaran, distribusi, dan penjualan produk biopharmaceutical. Perusahaan ini berkantor pusat di Princeton, New Jersey dan saat ini mempekerjakan 34.100 karyawan penuh waktu. Perusahaan ini terlibat dalam penemuan, pengembangan, dan pengiriman obat transformasional untuk pasien yang menghadapi penyakit serius di bidang: onkologi, hematologi, imunologi, kardiovaskular, neurosciences, dan bidang lainnya. Portofolio pertumbuhannya mencakup Opdivo (nivolumab), Opdivo Qvantig (nivolumab dan hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab dan relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), dan Sotyktu (deucravacitinib). Produk pertumbuhan lainnya termasuk Onureg, Inrebic, dan Empliciti. Portofolio legasinya mencakup Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), dan Abraxane (partikel paclitaxel terikat albumin untuk suspensi injeksi). Opdivo (nivolumab) adalah antibodi monoklonal manusia sepenuhnya yang mengikat PD-1 pada sel T dan NKT.

Bristol-Myers Squibb

NVIDIA

Microsoft

Apple

Google

Amazon

Meta Platforms

Broadcom

Taiwan Semiconductor

Tesla

Berkshire Hathaway

JPMorgan

Walmart

Oracle

Eli Lilly

Visa

MasterCard

Exxon Mobil

Netflix

Johnson & Johnson

Palantir

SPDR S&P500 ETF

ASML

Alibaba

Costco

AbbVie

Bank of America

Home Depot

Procter & Gamble

UnitedHealth Group

General Electric

Chevron

Vanguard Total Stock Market ETF

Coca-Cola

Cisco

Toyota

Wells Fargo

Morgan Stanley

AstraZeneca

American Express

Micron Technology

T-Mobile

Caterpillar

Salesforce

Goldman Sachs

Novartis

Raytheon Technologies

Philip Morris

Shopify

Novo Nordisk

Abbott

Merck

Shell

McDonald's

Royal Bank of Canada

Linde PLC

PepsiCo

Invesco QQQ Trust

Disney

Uber

Arista Networks

Intel

Lam Research

ServiceNow

Intuitive Surgical

QUALCOMM

Applied Materials

Blackstone

Intuit

AT&T

Citigroup

BlackRock

Sony

NextEra Energy

Charles Schwab

Boeing

Verizon

Booking Holdings

Amgen

Accenture

Danaher

S&P Global

Adobe

Unilever

Boston Scientific

Gilead Sciences

Banco Santander

Palo Alto Networks

Texas Instruments

Toronto-Dominion Bank

Pfizer

Capital One

CrowdStrike

Spotify

Lowe's

Bristol-Myers Squibb Stock

About Bristol-Myers Squibb

Key Statistics